FGFR1 Recombinant Monoclonal Antibody

1. myeloid/lymphoid neoplasms with FGFR1 rearrangement are a rare entity, with no distinct clinical phenotype. FGFR rearrangement confirmation by FISH should be performed in any hematological malignancy with 8p translocation. PMID: 29119847
2. CCND1 , C-MYC , and FGFR1 amplifications were observed in 34.28%, 28.57%, and 17.14% of the 35 samples (invasive ductal breast carcinoma). PMID: 30119151
3. High FGFR1 expression is associated with Peritoneal Dissemination Via Epithelial-to-Mesenchymal Transition in Gastric Cancer. PMID: 29976636
4. The present study aimed to evaluate the relationship between a common FGFR1 single nucleotide polymorphism (rs13317) with craniofacial morphology. PMID: 29872111
5. Clinical outcomes of myeloid/lymphoid neoplasms with fibroblast growth factor receptor-1 (FGFR1) rearrangement PMID: 29486661
6. Suggest that genomic alterations involving the cell cycle (TP53, CCND1, CDKN2A), as well as FGFR1 amplifications and tumour genomic alterations burden are prognostic biomarkers of survival in head and neck squamous cell carcinoma. PMID: 29331751
7. novel heterozygous frameshift mutation c.299_300insCCGCAGACTCCGGCCTCTATGC (p.C101Rfs*17) associated with Kallmann syndrome PMID: 29658329
8. FGFR3, as well as its downstream regulatory PI3K/AKT kinases, may serve as potential biomarkers for the invasiveness and prognosis of laryngeal cancer. PMID: 29299828
9. Our experiments presented a new mechanism adopted by GDNF supporting glioma development and indicated a possible therapeutic potential via the inhibition of proN-cadherin/FGFR1 interaction. PMID: 29750313
10. There was no significant difference in the expression of FGFR1 between different types of circulating tumor cells. PMID: 29764586
11. Our data may facilitate design of therapeutically relevant targeting molecules for selective treatment of FGFR1 overproducing cancers PMID: 29748524
12. Study finds infrequent BRAF alterations but enriched FGFR alterations in adults as compared with that reported in pediatric pilocytic astrocytomas. In addition, coexistent BRAF and FGFR alterations and a significant association of FGFR alterations with age and tumor location were noted. PMID: 27608415
13. SNP rs17182023 was correlated to reduced breast cancer risk, and was associated with FGFR1 protein expression. High FGFR1 protein expression was an independent risk factor of breast cancer, and resulted in poor prognosis. PMID: 29996114
14. Besides RET and HRAS, FGFR1 is only the third protooncogene found to be recurrently mutated in pheochromocytomas. PMID: 29159601
15. For the treatment of patients with breast cancer and FGFR1 amplifications. PMID: 29223982
16. presentation of the atomic structure of a 1:1:1 ternary complex that consists of the shed extracellular domain of alpha-klotho, the FGFR1c ligand-binding domain, and FGF23; in this complex, alpha-klotho simultaneously tethers FGFR1c by its D3 domain and FGF23 by its C-terminal tail, thus implementing FGF23-FGFR1c proximity and conferring stability PMID: 29342138
17. Study identified FGFR1, a promoter of glycolysis-related enzyme, as the target of miR-361 that promoted glycolysis and repressed oxidative phosphorylation in breast cancer cells. FGFR1 mediated the anti-glycolytic function of miR-361 by regulating the activity of PDHK1 and LDHA. PMID: 29132384
18. FGFR1 and/or FGF3 gene amplification correlated with a lower pathologic complete response in patients with HER2(+) early breast cancer treated with neoadjuvant anti-HER2 therapy. PMID: 28381415
19. Data demonstrated that FOXC1 binds to an Fgfr1 upstream regulatory region and that FOXC1 activates an Fgfr1 promoter element. Furthermore, elevated expression of Foxc1 led to increased Fgfr1-IIIc transcript promoting invasion after TGFbeta1-induced EMT. PMID: 28684636
20. These results suggest that FGFR1 gene amplification is a frequent alteration in squamous cell carcinoma of the lung and appears not to be a negative but rather a favorable prognostic marker for women and particularly for patients with advanced disease PMID: 29270870
21. These data suggest the ERalpha pathway remains active in estrogen-deprived ER(+)/FGFR1-amplified breast cancers. Therefore, these tumors are endocrine resistant and should be candidates for treatment with combinations of ER and FGFR antagonists. PMID: 28751448
22. Amplification of gene FGFR1 is associated with lung adenocarcinoma. PMID: 28381877
23. Lysosomal sequestration - resulting in an organelle-specific and pH-dependent nintedanib fluorescence - was identified as an intrinsic resistance mechanism in FGFR-driven lung cancer cells. Accordingly, combination of nintedanib with agents compromising lysosomal acidification (bafilomycin A1, chloroquine) exerted distinctly synergistic growth inhibitory effects PMID: 28882160
24. the close proximity between AcSDKP and FGFR1 was essential for the suppression of TGFbeta/smad signaling and EndMT associated with MAP4K4 phosphorylation (P-MAP4K4) in endothelial cells. PMID: 28771231
25. This study reports a highly specific internalizing antibody fragment that can serve as a therapeutic targeting agent for efficient delivery of cytotoxic drugs into FGFR1-positive lung cancer cells. PMID: 28483948
26. anlotinib inhibits the activation of VEGFR2, PDGFRbeta and FGFR1 as well their common downstream ERK signaling PMID: 29454091
27. Missense mutations in COL6A1, COL11A2, FGFR1, and BMP2 genetically predispose patients to ossification of posterior longitudinal ligaments. PMID: 27246988
28. High levels of FGFR1 is associated with non-small cell lung cancer. PMID: 28558758
29. The results of this study designate nFGFR1 signaling as a potential common dysregulated mechanism in investigated patients and potential therapeutic target in schizophrenia. PMID: 28094170
30. Findings indicate the great variability of fibroblast growth factor receptor 1 (FGFR1) mutation phenotypes in idiopathic hypogonadotropic hypogonadism (IHH) or Kallmann syndrome (KS). PMID: 28008864
31. these results show that FGFR1 polymorphism influences lower anterior face height, the distance from the upper lip to the nasal floor, and lip shape PMID: 28415752
32. Fibrolamellar carcinomas show polysomy of chromosome 8 and the FGFR1 locus, and only modest mRNA expression and weak or absent expression at the protein level. FGFR2 rearrangement was not detected. PMID: 26259677
33. endothelin-A receptor-activated ABCB1 expression has a role in nintedanib resistance in FGFR1-driven small cell lung cancer PMID: 27367030
34. Loss of FGFR1 does generate a gene signature that is reverse correlated with FGFR1 gene amplification and/or upregulation in human breast cancer. Our results suggest that FGFR1 signaling is a key pathway driving breast cancer lung metastasis and that targeting FGFR1 in breast cancer is an exciting approach to inhibit metastasis. PMID: 28433771
35. Combination treatment with AKT and FGFR kinase inhibitors have additive effects on malignant phenotypes in vitro and in vivo by inhibiting multiple signaling pathways and mitigating the compensatory upregulation of FGFR signaling induced by AKT kinase inhibition. PMID: 28008155
36. FGFR1/MAPK may be important for brachyury activation in lung cancer, and this pathway may be an appealing therapeutic target for a subset of brachyury-driven lung cancer. PMID: 27893433
37. FGFR1 alteration mainly represented by FGFR1-ITD is a frequent event in dysembryoplastic neuroepithelial tumors. Digital droplet PCRtrade mark is an easy and alternative method than whole-genome sequencing to detect FGFR1-ITD in Formalin-fixed paraffin-embedded brain tumors, in routine practice. PMID: 27791984
38. Report dramatic upregulation of fibroblast growth factor receptor 1 (FGFR1) and its cognate ligand FGF2 in both acquired and inherently resistant breast cancer cells. PMID: 27825137
39. This study reveals a stringent association between FGFR and the downstream effector c-Myc in FGFR-dependent cancers, and suggests the potential therapeutic value of c-Myc in FGFR-targeted cancer therapy. PMID: 27401245
40. Elevated FGFR3 and FGFR1 protein expression is common in aggressive ependymomas but likely not driven by genetic alterations. Further studies are warranted to evaluate whether ependymoma patients with high FGFR3 and/or FGFR1 expression could benefit from treatment with FGFR inhibitor based therapeutic approaches currently under evaluation in clinical trials PMID: 28468611
41. These data identify FGFR1 as a driver gene in multiple soft-tissue sarcoma subtypes and support FGFR1 inhibition, guided by patient selection according to the FGFR1 expression and monitoring of MAPK-ERK1/2 signaling, as a therapeutic option in this challenging group of diseases PMID: 27535980
42. Our results demonstrated that the AcSDKP-FGFR1 signaling pathway is critical for maintaining mitochondrial dynamics by control of miR let-7b-5p in endothelial cells. PMID: 29269295
43. increased FGFR1 CN was observed in two racial groups not previously reported: African Americans and Native Americans. However, FGFR1 amplification is not prognostic in laryngeal squamous cell carcinomas PMID: 29351293
44. This brief communication reports on a patient with an exceedingly rare "8p11 (eight-p-eleven) myeloproliferative syndrome" (EMS) with CEP110-FGFR1 rearrangement who responded to treatment with the multi-tyrosine kinase inhibitor (TKI) dasatinib PMID: 28242791
45. Identify mutually exclusive activating hotspot mutations in FGFR1 and related PI-3K/RAS signaling genes in malignant phyllodes tumors which are implicated in tumor pathogenesis and/or progression. PMID: 27255162
46. we report FGFR1 as being frequently overexpressed in HNSCC and as a candidate prognostic biomarker in HPV-negative HNSCC. PMID: 26936917
47. Head and neck cancers are recurrently affected by FGFR1 amplification, with a predominance in cancers of the oral cavity. PMID: 29022097
48. High FGFR1 expression is associated with non-small cell lung cancer. PMID: 26936993
49. Study present a rare case of a 46,XY patient with CHD associated with ambiguous genitalia consisting of a clitoris-like phallus and a bifid scrotum. Exome sequencing revealed novel homozygous mutations in the FGFR1 and STARD3 genes that may be associated with the phenotype. PMID: 27055092
50. PDGFRalpha levels are regulated by SMARCB1 expression, and assessment of clinical specimens documents the expression of both PDGFRalpha and FGFR1 in rhabdoid tumor patients. PMID: 27783942

Show More

Hide All

HGNC: 3688

OMIM: 101600

KEGG: hsa:2260

STRING: 9606.ENSP00000393312

UniGene: Hs.264887